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Mutations in the 50 UTR of ANKRD26, the Ankirin
Repeat Domain 26 Gene, Cause an Autosomal-Dominant
Form of Inherited Thrombocytopenia, THC2
Tommaso Pippucci,1 Anna Savoia,2,3 Silverio Perrotta,4 Nu´ria Pujol-Moix,5 Patrizia Noris,6
Giovanni Castegnaro,1 Alessandro Pecci,6 Chiara Gnan,2 Francesca Punzo,4,7 Caterina Marconi,1
Samuele Gherardi,8 Giuseppe Loffredo,9 Daniela De Rocco,3 Saverio Scianguetta,4 Serena Barozzi,6
Pamela Magini,1 Valeria Bozzi,6 Luca Dezzani,6 Mariateresa Di Stazio,2 Marcella Ferraro,4
Giovanni Perini,8 Marco Seri,1,* and Carlo L. Balduini6
THC2, an autosomal-dominant thrombocytopenia described so far in only two families, has been ascribed to mutations in MASTL or
ACBD5. Here, we show that ANKRD26, another gene within the THC2 locus, and neitherMASTL nor ACBD5, is mutated in eight unre-
lated families. ANKRD26 was also found to be mutated in the family previously reported to have an ACBD5mutation. We identified six
different ANKRD26mutations, which were clustered in a highly conserved 19 bp sequence located in the 50 untranslated region. Muta-
tions were not detected in 500 controls and are absent from the 1000 Genomes database. Available data from an animal model and
Dr. Watson’s genome give evidence against haploinsufficiency as the pathogenetic mechanism for ANKRD26-mediated thrombocyto-
penia. The luciferase reporter assay suggests that these 50 UTRmutations might enhance ANKRD26 expression. ANKRD26 is the ancestor
of a family of primate-specific genes termed POTE, which have been recently identified as a family of proapoptotic proteins. Dysregu-
lation of apoptosis might therefore be the pathogenetic mechanism, as demonstrated for another thrombocytopenia, THC4. Further
investigation is needed to provide evidence supporting this hypothesis.Inherited thrombocytopenias are a heterogeneous group
of diseases characterized by a reduced number of blood
platelets and a bleeding tendency that ranges from very
mild to life threatening.1 Fifteen forms of inherited throm-
bocytopenias are described in OMIM (Online Mendelian
Inheritance in Man). For some forms, the genetic defect
has been identified in one of the many genes participating
in the complex processes of megakaryopoiesis and platelet
production, whereas for other forms the gene that is
mutated is still unknown.1,2 Moreover, nearly 40% of
patients with an inherited form of thrombocytopenia
remain without a definite diagnosis because their condi-
tion has never been described or was not recognized as
pertaining to a known disorder.3
Thrombocytopenia 2 (THC2 [MIM 188000]) is one of the
rarest forms of autosomal-dominant thrombocytopenia. It
has so far been reported in only two families, one from
Italy and the other from North America.4,5 THC2-affected
individuals had a degree of thrombocytopenia ranging
from mild to severe and suffered from a mild bleeding
diathesis without any major bleeding events. Morpholog-
ical platelet studies did not identify any relevant defect,
and in vitro studies did not reveal any functional abnor-
mality. Thrombocytopenia was attributed to defective
platelet production because examination of bone marrow1Medical Genetics Unit, Department of Gynaecological, Obstetric, and Paedia
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The Amerfound evident dysmegakaryocytopoietic phenomena in
both families. The THC2 locus was mapped to chromo-
some 10p11.1-p12 through linkage analysis in two inde-
pendent studies.4,5 Two missense changes in different
linked genes were found to be causative of the disease:
c.501G>C (p.Glu167Asp) (please note that this mutation
was incorrectly named as c.565G>C in the original publi-
cation)6 of MASTL ([MIM 608221], NM_032844.3) in the
North American family6 and c.22C>T (p.His8Tyr) of
ACBD5 (NM_001042473.2) in the Italian one.7 Here we
report evidence that, at least in the families we studied,
THC2 does not derive from defects in either MASTL or
ACBD5 but is associated with mutations in a third gene
mapping to the same locus.
We studied four pedigrees of Italian ancestry in which
20 individuals showed a clinical phenotype consistent
with THC2, in that they had autosomal-dominant, non-
syndromic thrombocytopenia without any morpholog-
ical or functional platelet defect. Written informed
consent was obtained from all study subjects or their
parents or legal guardians. This study was approved by
the Institutional Review Board of the IRCCS Policlinico
San Matteo Foundation and was conducted according
to Declaration of Helsinki principles. When all known
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Figure 1. Linkage to Chromosome 10p11.1-p12 in Four THC2 Families
Segregation of microsatellite marker haplotypes in the THC2 locus on chromosome 10p11.1-p12 (with the correspondingMb positions)
in the two large THC2-linked families (Family 1 and 2) and in the two smaller families (families 3 and 4). Black symbols indicate affected
individuals, and white symbols indicate healthy ones. Slashed symbols mean that those individuals are deceased. Only individuals for
whom the corresponding haplotypes are reported were genotyped. Families 1 and 2, which carry the c.-128G>A and c.-127A>T muta-
tions, respectively (Table 1), are consistent with linkage at the THC2 locus. Families 3 and 4 do not provide significant LOD scores, but
their 10p11.1-p12 region segregates consistently with the disease. Family 3 carries the c.-118C>T mutation (Table 1). No mutation in
ANKRD26 was found in the affected members of family 4, and therefore segregation of the haplotype is probably not related to the
disease in this family. A 0/0 in the haplotypemeans unsuccessful genotyping for themarker in that individual. Haplotype representation
was obtained with Haplopainter version 1.0.17
Table 1. ANKRD26 50 UTR Mutations Identified in Nine Families
with Autosomal-Dominant Thrombocytopenia and Normal Platelet
Size
Family Mutation
Affected
subjects
Healthy
subjects Origin
1 a c.-128G>A 7 5 Italy
2 a c.-127A>T 6 3 Italy
3 a c.-118C>T 3 1 Italy
5 c.-116C>T 3 2 Italy
6 c.-134G>A 2 0 Italy
9 c.-125T>G 2 0 Italy
10 c.-128G>A 3 0 Italy
12 c.-127A>T 2 0 Argentina
Savoia et al.b;
Punzo et al.b
c.-134G>A 7 5 Italy
The number of affected and healthy members of each family tested for
ANKRD26 mutations is reported.
a Families studied by linkage analysis (Figure 1).
b Family described by Savoia et al.4 and Punzo et al.7excluded, linkage to the THC2 locus was investigated.
Linkage analysis was performed with Merlin version
1.1.28 under a completely penetrant autosomal-dominant
model with disease allele frequency of 0.0001. We
selected nine microsatellite markers (D10S586, D10S572,
D10S1775, D10S197, D10S111, D10S593, CArepeat1,
CArepeat2, and D10S174) across the THC2 locus. All
these markers were selected from the Marshfield Genetic
Map, except for markers CArepeat1 and CArepeat2,
which were identified directly from the genome sequence
via the on-line tool Tandem Repeat Finder (Table S1). All
available family members were genotyped, and the corre-
sponding haplotypes are represented in Figure 1. Marker
allele frequencies were inferred from genotyped individ-
uals, and average male/female inter-marker cM distances
were drawn from the Marshfield Genetic Map. Best haplo-
types were estimated with the haplotyping function
implemented in Merlin. Of the two larger pedigrees, pedi-
gree 1 exceeded genome-wide significance for linkage at
marker CArepeat1 with a pairwise LOD score of 3.31,
whereas pedigree 2 showed consistent linkage to THC2
with a pairwise LOD score of 2.35 (Figure 1 and Table 2).
In the two smaller pedigrees 3 and 4, a 10p11.1-p12
haplotype was transmitted consistently with disease
segregation (Figure 1), but LOD scores were not signifi-116 The American Journal of Human Genetics 88, 115–120, January 7cant because of the small size of the families (Table 2).
Therefore, we searched for mutations in the coding exons
and the respective flanking intronic regions of both, 2011
Figure 2. The 50-UTR-Mutated
Sequences of ANKRD26
(A) Alignment of the 50 UTRs of orthologs
from Homo sapiens (Hs: NM_014915.2),
Macaca mulatta (Mm: XM_002808496.1),
and Bos taurus (Bt: NM_001113767.1).
Nucleotide changes are in bold. Stars indi-
cate matching sites.
(B) Electropherograms showing the six
different heterozygous mutations identi-
fied in THC2 families (Table 1) .MASTL and ACBD5 in probands from the four families.
The analysis identified a few SNPs present in dbSNP but
did not disclose any unreported variants. Because most
of the SNPs were detected in the heterozygous state, we
could also exclude large intragenic deletions (data not
shown).
Recombination events in the pedigrees we analyzed did
not refine the THC2 locus, suggesting that a defect in
a gene other than MASTL or ACBD5 is responsible for
THC2. We therefore analyzed all the other 30 genes in
the critical region defined by previous studies. Analysis of
the entire coding sequences of all the positional candidate
genes detected only known polymorphisms (data not
shown). Interestingly, while we were sequencing the 50
and 30 untranslated regions (UTRs), we observed different
heterozygous single nucleotide substitutions within the 50
UTR of ANKRD26 (NM_014915.2). Nucleotide changes
c.-118C>T, c.-127A>T, and c.-128G>A were described in
probands from pedigrees 3, 2, and 1, respectively. We
then decided to screen the 50 UTR of ANKRD26 in 15
additional families, and in the family originally reported to
carry a mutation in ACBD54,7. In seven patients from this
last family, as well as in another pedigree, the c.-134G>A
transition was found, whereas in four other families,
c.-127A>T, c.-128G>A, or two further changes, c.-125T>G
and c.-116C>T, were detected (Table 1; see also Figure S1).The American Journal of Human GThese variants, which always segre-
gated with the linked haplotype along
the pedigrees, were not found in 500
controls, nor were they reported in
the 1000 Genomes database.
In total, six different ANKRD26
mutations were associated with
thrombocytopenia in all the 35 geno-
typed patients in nine out of 20
independent families, and one of
these mutations was found in the
original linkage family4. All of them
were located in a stretch of 19 nucleo-
tides of the 50 UTR that is conserved
among primates and cattle (Fig-
ure 2). Only affected individuals
from each family carry the mutation,
thus confirming complete penetrance
of the trait.These findings indicate that the ANKRD26 mutations
cause thrombocytopenia (Table 1) and support the idea
that the p.His8Tyr mutation of ACBD5 segregating within
the family is a private rare variant linked to the THC2
locus, rather than being related to the pathogenesis of
thrombocytopenia.
ANKRD26 is the ancestor of a family of primate-specific
genes termed POTE (Prostate-, Ovary-, Testis-, and
placenta-Expressed genes) whose expression is restricted
to a few normal tissues and a larger number of pathological
tissues, such as breast cancer and many other cancers.9
With regard to human bone marrow cells, Macaulay
et al. reported that ANKRD26 is expressed in megakaryo-
cytes, and, to a lesser extent, in erythroid cells.10
The functional role of ANKRD26 is unknown. Mutant
mice with partial inactivation of Ankrd26 develop extreme
obesity, insulin resistance, and increased body size,
whereas their platelet count is normal11 (T.K. Bera,
personal communication). The recently released DNA
sequence of James D. Watson’s genome shows that he
carries a heterozygous deletion of about 31.5 Kb involving
the last six exons of the gene (Database of Genomic Vari-
ants, Variation_39047), but clinical signs of thrombocyto-
penia are not reported.12 Taken together, these data suggest
that THC2 is more likely to be due to a gain of function
effect rather than a haploinsufficiency of ANKRD26.enetics 88, 115–120, January 7, 2011 117
Table 2. Single-Point and Multi-Point LOD Scores
Family 1 2 3 4
Marker Multi-Point LOD Score
D10S586 3.1519 2.2887 0.6021 0.2706
D10S572 3.3113 2.3979 0.6021 0.3010
D10S1775 3.3113 2.3979 0.6021 0.3010
D10S197 3.3113 2.3979 0.6021 0.3010
D10S111 3.3113 2.4082 0.6013 0.3010
D10S593 3.3113 2.4082 0.6021 0.3010
CArepeat1 3.3113 2.4082 0.6021 0.3010
CArepeat2 3.3113 2.4082 0.6021 0.3010
D10S174 3.3113 2.4082 0.6021 0.3010
Marker Two-Point LOD Score
D10S586 0.4700 0.3010 0.6021 0.0000
D10S572 2.7093 1.6428 0.6021 0.3010
D10S1775 1.4313 1.4109 0.4861 0.3010
D10S197 1.5065 0.2334 0.6021 0.3010
D10S111 3.2325 0.1087 0.5324 0.0000
D10S593 0.5523 0.5579 0.3010 0.3010
CArepeat1 3.3113 2.3502 0.6021 -
CArepeat2 1.5953 2.3087 0.6021 -
D10S174 2.0967 0.4113 0.6021 0.3
A recombination fraction of 0 was used for single-point scores. A dash stands
for ‘‘LOD score not calculated.’’
Figure 3. Firefly/Renilla RLU Ratios, Normalized against Wild-
Type, for Each of the 50 UTR Variants in the Functional Study
Scale bars represent means 5 standard deviation. Corresponding
values of each variant for – PMA/TPO Dami cells (light gray)
and þ PMA/TPO Dami cells (dark gray) are as follows:
c.-106T>C—0.73 5 0.16, 0.94 5 0.19; c.-127A>T— 1.09 5
0.26, 1.63 5 0.91; c.-128G>A—1.83 5 0.19, 3.37 5 0.36; and
c.-134G>A—1.84 5 0.49, 2.79 5 0.20. The assumption of
homogeneity of variances was respected both in PMA/TPO
and in þPMA/TPO Dami (Levene’s statistic > .13 and .36, respec-
tively). Normality of the distribution was respected for all the
samples (Kolmogorov-Smirnov Z Test). ANOVA rejected the null
hypothesis of equality of means in both groups. Significant
p values at the 5% level for a Dunnett’s test against the
c.-106T>C control are reported above the corresponding column
of the histogram.In order to define the pathogenetic effects of the 50
UTR mutations, we cloned the wild-type and three mutant
(c.-127A>T, c.-128G>A, and c.-134G>A) 50 UTR sequences
upstream of a reporter luciferase gene. These are the muta-
tions segregating in three families with conclusive LOD
scores, including the family in which the locus was origi-
nally mapped. We also included the c.-106T>C variant as
a control. The constructs were transiently transfected
into two different cell lines: the undifferentiated myeloid
K562 cells, which derived from blast crisis of human
chronic myelogenous leukemia, and the Dami cells,
a human megakaryoblastic cell line whose maturation
toward megakaryocytic lineage can be induced by treat-
ment with phorbol 12-myristate 13-acetate (PMA) and
thrombopoietin (TPO).13,14
To detect differences in expression, we performed
a dual-luciferase reporter assay. We first assayed the K562
cells and noticed an average increase in expression from
2.7 to 4.5 times for the c.-134G>A clone with respect to
all the other constructs. We then tested the megakaryo-
blastic Dami cells, either without or with PMA/TPO
stimulation to induce megakaryocytic maturation. We
performed a one-factor ANOVA to assess the effect of 50
UTR ANKRD26 mutations on gene reporter expression118 The American Journal of Human Genetics 88, 115–120, January 7levels in the two populations of cells and observed that
stimulated Dami cells showed marked differences in
expression among mutations (p< 0.001). Then, we carried
out a two-tailed Dunnett’s test for multiple comparisons
against the c.-106T>C as an internal control in Dami –
PMA/TPO and Dami þ PMA/TPO. In the first group, the
c.-128G>A and c.-134G>A but not the c.-127A>T
constructs overexpressed the reporter gene with respect
to the control. Finally, when we assayed Dami cells in
which stimulation with PMA and TPO had induced
megakaryocytic maturation (Figure S2), we observed
overexpression for all three mutations (p ¼ 0.016 for
c.-127A>T and p < 0.001 for c.-128G>A and c.-134G>A;
Figure 3).
We then estimated the relative contribution of muta-
tions and cell maturation to the variation in expression
with a two-factor ANOVA and found that the largest effect
was due to the presence of alterations in the 50 UTR
sequence (p < 0.001, partial h2 of 0.9) rather than to
PMA-TPO stimulation (p < 0.001, partial h2 of 0.73). This
is consistent with a scenario in which the mutation inter-
feres with reporter gene expression, and cell maturation
toward a megakaryocytic lineage then amplifies this effect.
On the basis of these results, we can speculate that the
mutations observed in THC2 patients interfere with the, 2011
mechanisms controlling the expression of ANKRD26 and
affect megakaryopoiesis and platelet production, possibly
by induction of apoptosis. Recently, Liu et al. identified
POTE as a new family of proapoptotic proteins.15 Morison
et al. demonstrated that a different autosomal-dominant
thrombocytopenia (THC4, [MIM 612004]) derives from
increased apoptotic activity due to a cytochrome c muta-
tion.16 Their observations suggest that platelet formation
is particularly sensitive to changes in the intrinsic
apoptotic pathway. Bone marrow examination, performed
in two patients with different ANKRD26 mutations (fami-
lies 3 and 12), showed that megakaryocytes were present
in normal number and that all their maturation stages
were represented. This observation, although preliminary,
suggests that thrombocytopenia could derive from a
defect of platelet release and/or a reduced platelet life
span. The preliminary expression data we present support
but do not prove that increased expression and subsequent
apoptosis in megakaryocytes is a plausible pathogenic
mechanism. These arguments will direct further investiga-
tion aimed at clarifying the molecular events leading to
THC2.
We conclude that mutations in the 50 UTR of ANKRD26
are implicated in THC2. Analysis of this gene in the North
American family previously described6 will clarify whether
THC2 is a genetically heterogeneous disease or the MASTL
variant is benign.Supplemental Data
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